...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cell cycle >Inhibition of cancer progression by rifampicin: involvement of antiangiogenic and anti-tumor effects.
【24h】

Inhibition of cancer progression by rifampicin: involvement of antiangiogenic and anti-tumor effects.

机译：利福平抑制癌症进展：参与抗血管生成和抗肿瘤作用。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Very recently, we reported that an antituberculous agent, rifampicin, exerts potent inhibitory effects on hepatic tumors when administered orally at low doses. The in vitro effects of rifampicin to rapidly downregulate angiogenesis and mitogenesis-related genes in cultured endothelial cells are reminiscent of endostatin, one of the most well-studied angiogenesis inhibitors. However, rifampicin at the expected hepatobiliary concentrations after low oral doses showed more complete antiproliferative effects on endothelial cells, which make rifampicin favorable as an adjunct anticancer regimen. Since rifampicin undergoes hepatic accumulation resulting from the enterohepatic circulation, it may be especially beneficial for targeting hepatobiliary tumors. In the present paper, we extend our observations on the antiangiogenic properties of rifampicin and further elaborate on its direct antitumor effects on a variety of human cancer-derived cells.
机译：最近，我们报告说，口服低剂量的抗结核药利福平可对肝肿瘤产生有效的抑制作用。利福平在培养的内皮细胞中快速下调血管生成和有丝分裂相关基因的体外作用让人想起内皮抑素，内皮抑素是研究最深入的血管生成抑制剂之一。然而，低剂量口服后，利福平在预期的肝胆浓度下显示出对内皮细胞更完全的抗增殖作用，这使得利福平成为辅助的抗癌方案。由于利福平会因肠肝循环而发生肝积累，因此对于靶向肝胆肿瘤可能特别有益。在本文中，我们扩展了对利福平抗血管生成特性的观察，并进一步阐述了其对多种人类癌症衍生细胞的直接抗肿瘤作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号